Gain Therapeutics, Inc.

Magellan · Minoryx Therapeutics

Computational target and drug discovery platform using AI-driven structure-based virtual screening to identify novel allosteric binding sites on disease-implicated proteins and discover proprietary small molecule structurally targeted allosteric regulators (STARs). Disease focus areas include CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology.

Magellan

Proprietary allosteric drug discovery platform enabling identification of novel small molecule modulators that restore or disrupt protein function; disease focus includes neurodegenerative diseases, rare genetic disorders (lysosomal storage disorders), and oncology

Targets: GCase, β-galactosidase